Oncology
5,176 studies502 in 7 days2,477 in 30 days
Filters
Latest
5,176 studies
- Prediction of lncRNA–cervical cancer associations using a multi-view collaborative variational autoencoder with knowledge distillation transfer learning
- 170 Enhancing γδ CAR T cell function through alternative CD3 cytoplasmic domains
- 1141 Spatial immune profiling across the lobular breast cancer continuum reveals progressive immune exclusion from precursor lesion to invasive disease
- 1135 Tumor intrinsic PDL1 promotes resistance to PARP inhibitors (PARPi) and select chemotherapies through Chk2 stabilization in bladder cancer
- 838 ETV6 rearrangements impair T cell infiltration via activating β-Catenin signaling in triple-negative breast cancer
- 400 Proinflammatory and immune checkpoint responses in bystander tumor cells in an in vitro breast cancer model
- 64 Explainable AI for objective immunohistochemistry antibody clone selection, failure attribution, and optimization
- 618 A novel preclinical mouse model to investigate IL-18-targeting therapies
- 1078 Mutational signatures as mechanistic biomarkers of tumor immunity: associations with TMB, PD-L1 and immune phenotypes across cancer types
- Quantifying a Neglected Burden: Pregnancy-Associated Hepatocellular Carcinoma and Maternal Death in South Africa
- 563 Updated safety and efficacy of AN4005, an oral small-molecule PD-L1 inhibitor, in advanced solid tumors: phase I dose-escalation and expansion
- 556 A phase I first-in-human trial of IL-12 genetically engineered myeloid cells in participants with relapsed, refractory solid tumors
- 207 Off-the-shelf DLL3/CD70 dual CAR T cells with optimized site-specific integration for SCLC and neuroendocrine tumors
- 1121 Insights from orthotopic tumor engraftment in humanized mice
- 68 Translational PET imaging of suppressive granulocytic myeloid cells in glioblastoma
- 336 The impact of tumor genomics and tissue context on tumor-reactive T cell states
- Beyond Manufacturing Feasibility: From Point-of-Care Manufacturing to Point-of-Care Implementation
- 971 The impact of liver metastases on immune-related adverse events in stage IV patients treated with immune-checkpoint inhibitors: a real-world, multicenter, retrospective study
- 962 Immune related hepatitis is associated with improved survival in patients with melanoma and liver metastases
- 401 genO-hCCR8/hCCL1/hFcγR preclinical mouse model for efficacy assessment of CCR8-targeting agents
- 47 AI-assisted cytometry panel design for cancer immunotherapy
- 1076 Patient-derived organoids reveal tumor-restricted noncanonical HLA-I antigen candidates in low mutation burden metastatic melanoma
- 166 CARD8- and SRCAP-deficient CAR T-cells promote durable responses and limit functional exhaustion
- 1144 Spatially organized cytokine responses in malignant cells predict immunotherapy response
- 203 Dual targeting of uPAR and MICA/B with multiplexed-engineered CAR T cells offers a unique therapeutic strategy in fibrotic disease